ExpreS2ion Biotech: Signs Letter of Intent with WuXi Vaccines to initiate technology evaluation of ExpreS2ion’s proprietary production platform ExpreS2™

ExpreS2ion Biotechnologies is expected to release its Q1 2025 results on 15 May 2025. Later on the same day at 10:30, the management will present the results and the achievements in an online live presentation. The presentation will be followed by a Q&A session.

ExpreS2ion has today informed the market about the progress on the HER2 breast cancer vaccine candidate, ES2B-C001, but also announced that they will no longer pursue the development of a CMV candidate, a collaboration with Evaxion Biotech.

Today, ExpreS2ion Biotechnologies’ CFO Keith Alexander presented the results and update on business for the fourth quarter of 2024. Furthermore, they gave some insight into the business case around the Breast cancer candidate currently commencing phase 1.

ExpreS2ion Biotechnologies is expected to release its Q4 2024 results on 6 February 2025. On the same day at 10:00, the company’s and CFO Keith Alexander will present the results and the achievements in an online live presentation. The management presentation will be followed by a Q&A session.

ExpreS2ion Biotech (One-pager): Market value below cash balance

Together with ExpreS2ion Biotechnologies' CEO, Bent Frandsen, we looked back at the main achievements in 2024, which was the first year of implementing the new strategy. The company has focused on leveraging the platform to advance assets with shorter development timelines, and it has also been a year with good progress in the pipeline. In the interview, you can hear more about the progress of the breast cancer candidate, external validation through partnerships, and lastly which milestones investors should look out for in 2025.